ProMIS Neurosciences

PMN

Market cap $22.8M

Overview Fund Activity

0.4399 USD

+0.0219

5.24%

At close Updated Sep 12, 4:00 PM EDT

Pre-market

After hours

0.4226

-0.0173

3.93%

1 day

5.24%

5 days

5.37%

1 month

-37.16%

3 months

-15.4%

6 months

-42.41%

Year to date

-54.18%

1 year

-64.81%

5 years

-95.24%

10 years

-95.24%

About: ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins.

Employees: 8

Healthcare Biotechnology

0

Funds holding %

of 7,462 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

100% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 3

19% more funds holding

Funds holding: 16 [Q1] → 19 (+3) [Q2]

2.57% less ownership

Funds ownership: 28.49% [Q1] → 25.92% (-2.57%) [Q2]

37% less capital invested

Capital invested by funds: $6.49M [Q1] → $4.1M (-$2.39M) [Q2]

75% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 4

See Fund Rankings

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target

$4

809% upside

Avg. target

$4

809% upside

High target

$4

809% upside

1 analyst rating

1 positive

100%

0 neutral

0%

0 negative

0%

HC Wainwright & Co.

Raghuram Selvaraju

$4

Buy

Initiated

14 Jul 2025

See Analyst Rankings

Financial journalist opinion

ProMIS Neurosciences Receives DSMB Approval to Advance to Final Dose Escalation Cohort in Phase 1b Alzheimer's Trial of PMN310

Cohort 2 fully enrolled; enrollment and dosing now underway for Cohort 3 (final dose level); No cases of amyloid-related imaging abnormalities (ARIA) observed to date; The trial, expected to enroll 128 patients, remains on track to report 6-month interim data in Q2 2026 and final 12-month top-line results in Q4 2026. Cambridge, Massachusetts, Sept.

ProMIS Neurosciences Receives DSMB Approval to Advance to Final Dose Escalation Cohort in Phase 1b Alzheimer's Trial of PMN310

ProMIS Neurosciences Announces Second Quarter 2025 Financial Results & Corporate Highlights

U.S. FDA Grants Fast Track Designation for PMN310 in Alzheimer's Disease, enhancing program's potential for priority review PRECISE-AD Phase 1b Trial in Alzheimer's Disease Progressing on Schedule: Over 50% enrolled, no cases of ARIA and no patient dropouts to date Strengthened Financial Position with $21.6 Million in Gross Proceeds Raised in July 2025 Cambridge, Massachusetts, Aug. 13, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases, such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and Parkinson's disease (PD), today announced financial results for the second quarter ended June 30, 2025. “The team's exceptional focus and execution in the first half of 2025 culminated in what has been an extraordinary past month for ProMIS and its key stakeholders,” said Neil Warma, Chief Executive Officer of ProMIS Neurosciences.

ProMIS Neurosciences Announces Second Quarter 2025 Financial Results & Corporate Highlights

ProMIS Neurosciences to Showcase Protein-Misfolding Drug Discovery Platform & PRECISE-AD Trial Design at the 2025 Alzheimer's Association International Conference

Presentation to highlight the Company's proprietary protein-misfolding platform, EpiSelect TM , used to develop PMN310 Posters highlighting PRECISE-AD, the Company's Phase 1b clinical trial design and optimization of biomarkers in AD Progress with trial enrollment following DSMB recommendation to proceed to second dose level CAMBRIDGE, Massachusetts , July 29, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company committed to the discovery and development of therapeutic antibodies selective for toxic oligomers associated with the development and progression of neurodegenerative diseases such as Alzheimer's Disease (AD), amyotrophic lateral sclerosis (ALS) and Parkinson's disease (PD), today announced it has been invited to present an overview of its ongoing PRECISE-AD trial in Alzheimer's Disease (AD) and its proprietary Discovery Platform, EpiSelect TM , at the Alzheimer's Association International Conference 2025 (AAIC) taking place in Toronto, Canada from July 27-31, 2025. “We are pleased to share further details of our ongoing Phase 1b PRECISE-AD clinical trial evaluating PMN310, our novel therapeutic candidate for Alzheimer's disease,” said Dr. Larry Altstiel, M.D.

ProMIS Neurosciences to Showcase Protein-Misfolding Drug Discovery Platform & PRECISE-AD Trial Design at the 2025 Alzheimer's Association International Conference

ProMIS Neurosciences Announces Private Placement Financing

$3 million private financing plus an additional $9 million of proceeds due to exercise of warrants, for gross proceeds of approximately $12.0 million $3 million private financing plus an additional $9 million of proceeds due to exercise of warrants, for gross proceeds of approximately $12.0 million

ProMIS Neurosciences Announces Private Placement Financing

ProMIS Neurosciences Announces Private Placement Financing

TORONTO, Ontario and CAMBRIDGE, Massachusetts, July 22, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (Nasdaq: PMN), a clinical-stage biotechnology company committed to discovery and development of therapeutic antibodies targeting toxic misfolded proteins in neurodegenerative diseases, such as Alzhiemer's disease (AD), amyotrophic lateral sclerosis (ALS) and Parkinson's disease (PD), today announced that it has entered into a purchase agreement (the “Purchase Agreement”) with an existing institutional and accredited investor to issue and sell an aggregate of approximately $2.4 million of warrants (the “Warrants”). The Warrants were sold at a price of $0.1875 per share through a private investment in public equity (“PIPE”) financing.

ProMIS Neurosciences Announces Private Placement Financing

ProMIS Neurosciences Granted Fast Track Designation by U.S. FDA for PMN310 in the Treatment of Alzheimer's Disease

CAMBRIDGE, Mass., July 21, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company committed to the discovery and development of therapeutic antibodies targeting toxic misfolded proteins in neurodegenerative diseases, such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and Parkinson's disease (PD), today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to PMN310, the Company's lead therapeutic candidate in development for the treatment of Alzheimer's disease (AD).

ProMIS Neurosciences Granted Fast Track Designation by U.S. FDA for PMN310 in the Treatment of Alzheimer's Disease

ProMIS Neurosciences Granted Fast Track Designation by U.S. FDA for PMN310 in the Treatment of Alzheimer's Disease

FDA designation highlights the potential of PMN310 to deliver a more targeted approach to treating Alzheimer's Disease CAMBRIDGE, Mass., July 21, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company committed to the discovery and development of therapeutic antibodies targeting toxic misfolded proteins in neurodegenerative diseases, such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and Parkinson's disease (PD), today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to PMN310, the Company's lead therapeutic candidate in development for the treatment of Alzheimer's disease (AD).

ProMIS Neurosciences Granted Fast Track Designation by U.S. FDA for PMN310 in the Treatment of Alzheimer's Disease

ProMIS Neurosciences Presents at H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference

CAMBRIDGE, Massachusetts, June 17, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company committed to the discovery and development of therapeutic antibodies selective for toxic oligomers associated with the development and progression of neurodegenerative diseases such as Alzheimer's Disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), as well as other misfolded protein diseases, today announced that Neil Warma, Chief Executive Officer of ProMIS Neurosciences, will participate in a fireside chat at the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference today, June 17th, 2025 at 7:00 a.m.

ProMIS Neurosciences Presents at H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference

ProMIS Neurosciences Announces First Quarter 2025 Financial Results

First Cohort Completed in PRECISE-AD Trial Evaluating PMN310 in Alzheimer's Disease Six Month Interim Results Expected in 1H 2026 Topline Results Anticipated by end of 2026 CAMBRIDGE, Massachusetts, May 12, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases, such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), Parkinson's disease (PD) and multiple system atrophy (MSA), today announced financial results for the first quarter ended March 31, 2025. “We made significant progress in the first quarter of 2025, advancing our lead clinical program in Alzheimer's disease with rapid enrollment of the first cohort in the PRECISE-AD trial,” said Neil Warma, Chief Executive Officer of ProMIS Neurosciences.

ProMIS Neurosciences Announces First Quarter 2025 Financial Results

ProMIS Neurosciences Announces Full Year 2024 Financial Results and Recent Highlights

Rapid Enrollment and Dosing of First Patients in PRECISE-AD Trial Underscores the Unmet Need for Better Treatment Options for Alzheimer's Disease

ProMIS Neurosciences Announces Full Year 2024 Financial Results and Recent Highlights

See News Rankings

Charts implemented using Lightweight Charts™